F

FUREN Group Pharmaceutical Co Ltd
SSE:600781

Watchlist Manager
FUREN Group Pharmaceutical Co Ltd
SSE:600781
Watchlist
Price: 0.77 CNY Market Closed
Market Cap: ¥482.9m

Relative Value

There is not enough data to reliably calculate the relative value of FUREN Group Pharmaceutical Co Ltd.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
Not Available
F
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
FUREN Group Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
FUREN Group Pharmaceutical Co Ltd
SSE:600781
482.9m CNY 0.3 -0.2 -1.8 -1.8
US
Eli Lilly and Co
NYSE:LLY
987.6B USD 16.6 53.6 36 38.6
US
Johnson & Johnson
NYSE:JNJ
565.6B USD 6 21 14.6 17.9
CH
Roche Holding AG
SIX:ROG
280.6B CHF 4.6 30 12.7 14.8
UK
AstraZeneca PLC
LSE:AZN
214.3B GBP 5.1 31.8 15.2 22.2
CH
Novartis AG
SIX:NOVN
223.4B CHF 5.1 20 12.6 16.3
US
Merck & Co Inc
NYSE:MRK
291.6B USD 4.5 15.3 10.8 12.8
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.9 11 12.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
146.4B USD 2.3 14.7 7.5 10.2
FR
Sanofi SA
PAR:SAN
97.3B EUR 1.7 8.2 7.7 7.7
P/E Multiple
Earnings Growth PEG
CN
F
FUREN Group Pharmaceutical Co Ltd
SSE:600781
Average P/E: 23.4
Negative Multiple: -0.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.6
54%
1
US
Johnson & Johnson
NYSE:JNJ
21
6%
3.5
CH
Roche Holding AG
SIX:ROG
30
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.8
38%
0.8
CH
Novartis AG
SIX:NOVN
20
17%
1.2
US
Merck & Co Inc
NYSE:MRK
15.3
14%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.9
2%
8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
FR
Sanofi SA
PAR:SAN
8.2
1%
8.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
F
FUREN Group Pharmaceutical Co Ltd
SSE:600781
Average EV/EBITDA: 46.1
Negative Multiple: -1.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.6
2%
7.3
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
15.2
10%
1.5
CH
Novartis AG
SIX:NOVN
12.6
6%
2.1
US
Merck & Co Inc
NYSE:MRK
10.8
6%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
F
FUREN Group Pharmaceutical Co Ltd
SSE:600781
Average EV/EBIT: 98.9
Negative Multiple: -1.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.6
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.9
6%
3
CH
Roche Holding AG
SIX:ROG
14.8
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
22.2
23%
1
CH
Novartis AG
SIX:NOVN
16.3
12%
1.4
US
Merck & Co Inc
NYSE:MRK
12.8
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5
FR
Sanofi SA
PAR:SAN
7.7
6%
1.3